| Pharmaceutical Information |
| Drug Name |
Hepatitis b immune globulin (human) |
| Drug ID |
BADD_D01062 |
| Description |
Long-term hepatitis B immune globulin (HBIG) has been shown to reduce hepatitis B virus (HBV) reinfection in patients transplanted for hepatitis B. Infection with hepatitis B may lead to hepatocellular carcinoma, a type of liver cancer. Therefore, the hepatitis-B vaccines are cancer-preventing vaccines. According to the Centers for Disease Control and Prevention (CDC), the hepatitis B vaccine was the first anti-cancer vaccine.
HBIG is prepared from the plasma of donors who have high antibody levels of the hepatitis B surface antigen. It is extracted from the Cohn fraction II. During the process, viruses are deactivated, and in the final steps, solvents used in the preparation are removed. The preparation is tested for absence of HIV, HCV, herpes virus, and reovirus. |
| Indications and Usage |
Investigated for use/treatment in hepatitis (viral, B), liver transplant surgery, and pediatric indications. |
| Marketing Status |
approved; investigational |
| ATC Code |
Not Available |
| DrugBank ID |
DB05276
|
| KEGG ID |
Not Available
|
| MeSH ID |
C045213
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
69800-4203; 13533-636; 69800-4202 |
| UNII |
Not Available
|
| Synonyms |
hepatitis B hyperimmune globulin | human hepatitis B virus immune globulin | HBIG | hepatect |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
Not Available |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
|
